Schonfeld Strategic Advisors LLC Invests $1.63 Million in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Schonfeld Strategic Advisors LLC purchased a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 106,172 shares of the company's stock, valued at approximately $1,633,000. Schonfeld Strategic Advisors LLC owned 0.38% of ClearPoint Neuro at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CLPT. Barclays PLC boosted its holdings in ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after purchasing an additional 1,109 shares during the last quarter. NewEdge Advisors LLC grew its position in ClearPoint Neuro by 7.3% in the 4th quarter. NewEdge Advisors LLC now owns 21,114 shares of the company's stock worth $325,000 after purchasing an additional 1,431 shares during the last quarter. LPL Financial LLC increased its position in ClearPoint Neuro by 4.5% in the 4th quarter. LPL Financial LLC now owns 40,250 shares of the company's stock valued at $619,000 after acquiring an additional 1,750 shares during the period. R Squared Ltd acquired a new stake in ClearPoint Neuro in the fourth quarter worth about $32,000. Finally, Parsons Capital Management Inc. RI increased its position in shares of ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock valued at $2,177,000 after purchasing an additional 2,600 shares during the period. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Lake Street Capital increased their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, January 21st. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, B. Riley boosted their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

Shares of CLPT stock traded down $0.23 during trading hours on Monday, hitting $13.89. The company had a trading volume of 87,458 shares, compared to its average volume of 238,283. The firm's fifty day moving average is $12.85 and its 200 day moving average is $14.23. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22. The firm has a market capitalization of $388.50 million, a price-to-earnings ratio of -20.12 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $8.23 million. On average, sell-side analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.